Yes it will. An approval to sell in the worlds most profitable Biomed region will do it. As will actual sales in the EU, as then it moves from purely spec share to being a revenue making company which is a different beast that is treated by the market very differently. Time will tell if I am wrong on this I guess. What are your thoughts on my logic?
News: OSL Oncosil Medical Files For Registration Of Oncosiltm Device In U.S. Market, page-15
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
97.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $13.79M | |||
| Open | High | Low | Value | Volume |
| 99.5¢ | 99.5¢ | 97.0¢ | $5.603K | 5.712K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 4583 | 97.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 99.5¢ | 3684 | 2 |
View Market Depth
| Last trade - 10.24am 24/06/2025 (20 minute delay) ? |
| OSL (ASX) Chart |